ImmunoGen, Takeda to Develop and Commercialize ELAHERE® in Japan

 

• ImmunoGen to Receive $34 Million¹ in Upfront and Near-Term Milestone Payments and is Eligible to Receive Potential Regulatory and Commercial Milestone Payments as well as Double-Digit Royalties
• Collaboration Further Supports Strategy to Bring ELAHERE to Eligible Patients with Folate Receptor Alpha (FRα)-Positive, Platinum-Resistant Ovarian Cancer Globally

https://www.biospace.com/article/releases/immunogen-announces-collaboration-with-takeda-to-develop-and-commercialize-elahere-in-japan/